Brainsway Ltd. Expands Influence in Neuromodulation with Strategic Investments
Brainsway Ltd., a leading medical device company specializing in non-invasive neuromodulation products for treating major depressive disorder (MDD) and obsessive-compulsive disorder (OCD), has made significant strategic investments to expand its influence in the neuromodulation market. Listed on the Tel Aviv Stock Exchange, Brainsway has been actively pursuing opportunities to enhance its product offerings and market reach.
On August 21, 2025, Brainsway announced a strategic investment in Neurolief, a brain stimulation company developing non-invasive neuromodulation therapies. This investment is particularly noteworthy as Neurolief prepares for the launch of its Proliv™Rx system, a groundbreaking treatment for MDD. The Proliv™Rx system offers at-home brain neuromodulation therapy for patients who have not responded adequately to traditional antidepressants. Brainsway’s investment is aimed at leveraging its commercial expertise and global presence to support Neurolief’s impending FDA approval and commercial launch.
The partnership between Brainsway and Neurolief is expected to significantly enhance Brainsway’s total addressable market. By investing in Neurolief, Brainsway aims to broaden its portfolio of neuromodulation systems and strengthen its position as a global leader in non-invasive neurostimulation treatments for mental health disorders.
In addition to its investment in Neurolief, Brainsway has also been active in the mental health services sector. On August 20, 2025, the company invested $2.3 million in Axis, a mental health services provider, and acquired a minority stake in Axis Integrated Mental Health. These investments underscore Brainsway’s commitment to expanding its reach in the mental health market and enhancing its service offerings.
Financially, Brainsway has shown strong performance, with its stock reaching a 52-week high of 2562 ILS on August 19, 2025. The company’s market capitalization stands at 833,320,000 ILS, and it has a price-to-earnings ratio of 66.91. These figures reflect investor confidence in Brainsway’s growth prospects and strategic initiatives.
As Brainsway continues to invest in innovative neuromodulation technologies and expand its market presence, investors are keenly watching to see if the company’s recent gains can be sustained. With its strategic investments and focus on expanding its product and service offerings, Brainsway is well-positioned to capitalize on the growing demand for non-invasive treatments for mental health disorders.